Compare BDSX & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDSX | SNTI |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.0M | 53.6M |
| IPO Year | 2020 | N/A |
| Metric | BDSX | SNTI |
|---|---|---|
| Price | $7.85 | $1.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $32.50 | $9.00 |
| AVG Volume (30 Days) | 62.6K | ★ 4.1M |
| Earning Date | 11-03-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $80,173,000.00 | N/A |
| Revenue This Year | $20.75 | N/A |
| Revenue Next Year | $25.05 | $150.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.29 | N/A |
| 52 Week Low | $3.44 | $1.26 |
| 52 Week High | $32.20 | $5.96 |
| Indicator | BDSX | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 34.89 |
| Support Level | $7.77 | $1.34 |
| Resistance Level | $8.38 | $2.88 |
| Average True Range (ATR) | 0.57 | 0.25 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 60.38 | 2.48 |
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.